On October 4-5, Gelendzhik hosted the largest annual forum to discuss issues of the biomedical industry and the implementation of the national project “Health” – BIOTECHMED 2021.
The forum, which is one of the largest platforms for dialogue between the state and business, organized by the Ministry of Industry and Trade of the Russian Federation, was traditionally supported by the Ministry of Health of the Russian Federation, Rostech State Corporation and the Administration of the Krasnodar Territory.
Forum participants of the plenary session “Pandemics of the future. A New Reality for Industry, Regulators and Business” discussed technologies and solutions developed during the pandemic to build the state’s resilience to infectious threats. Speaking about the role of industry in ensuring the security of the state, Denis Manturov, the Minister of Industry and Trade, noted that the production volumes of the Sputnik V vaccine, personal protective equipment and medical equipment necessary to counter the coronavirus infection make it possible to cover the needs of the domestic healthcare system.
Vasily Osmakov, the First Deputy Minister of Industry and Trade, presented the Strategy for the Development of the Russian Pharmaceutical Industry for the period up to 2030 (“Pharma 2030”) to the forum participants. The strategy outlines three target areas: localization – ensuring full import independence in the production of strategically important medicines, innovation – stimulating the emergence of original drugs, demand/access to markets – ensuring affordability and quality of medicines for the national healthcare system and stimulating exports through harmonization of regulatory procedures.
The most subtle point in the intensive innovative development of any industry is the protection of intellectual property rights. Monopoly presence in the market allows the right holder to recover the costs of developing innovative products and invest the funds received in new developments. At the same time, a long-term monopoly leads to limited access to treatment for a wide range of patients and an increased financial burden on the national healthcare system.
The issues of improving legal regulation in the field of creating innovative products were discussed by the participants of the discussion session “IP in Pharmacy. Is a balance of interests possible?” Mikhail Fonarev, the General Director of the FSUE Moscow Endocrine Plant, in his speech focused on the methodology for protecting and contesting patents, the need to act exclusively in the legal field, involving competent expert organizations.
Comment type is not specified in the component properties.